Last week, Cara Therapeutics reported that its phase 2b trial of CR845, an investigational new pain relief drug, had failed to meet its primary endpoint. Since then, the stock dropped from $26 to $15 a loss of over 40% of its value. Has the market over-reacted?
from Forbes Real Time http://www.forbes.com/sites/kenkam/2017/07/06/cara-therapeutics-new-pain-drug-still-has-value-after-failed-clinical-trial/
via IFTTT
No comments:
Post a Comment